Skip to main content
ABBOTT LABORATORIES logo

ABBOTT LABORATORIES — Investor Relations & Filings

Ticker · ABT ISIN · US0028241000 LEI · HQD377W2YR662HK5JX27 US Manufacturing
Open in API
Filings indexed 4,256 across all filing types
Latest filing 2016-04-29 Director's Dealing
Country US United States of America
Listing US ABT

About ABBOTT LABORATORIES

https://www.abbott.com

Abbott Laboratories is a global healthcare company that discovers, develops, manufactures, and sells a broad portfolio of life-changing technologies. The company's operations are focused on four core businesses: Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals. The Medical Devices division offers solutions for cardiovascular health, diabetes care (including the FreeStyle Libre continuous glucose monitoring system), and neuromodulation. The Diagnostics segment provides a wide range of in vitro diagnostic systems and tests for hospitals, laboratories, and clinics. The Nutrition business develops and markets science-based nutritional products for people of all ages, with leading brands such as Similac, PediaSure, Ensure, and Glucerna. The Established Pharmaceuticals division provides a portfolio of branded generic medicines to consumers in emerging markets.

Recent filings

Filing Released Lang Actions
Statement of changes in beneficial ownership
Director's Dealing Classification · 100% confidence The document is a SEC Form 4 filing, which is a statement of changes in beneficial ownership of company securities by insiders such as officers or directors. It details transactions in the company's shares by a senior vice president, including dates, amounts, and prices. This type of filing is specifically used to report insider trades and personal share transactions by company directors and executives. It is not an earnings release, annual report, or any other type of financial or regulatory report. Therefore, the correct classification is Director's Dealing (DIRS). The document length and content confirm it is not an announcement or certification but the actual insider transaction report.
2016-04-29 English
8-K
M&A Activity Classification · 100% confidence The document is a Form 8-K current report filed with the SEC by Abbott Laboratories dated April 27, 2016. It announces the entry into a material definitive agreement, specifically an Agreement and Plan of Merger with St. Jude Medical, Inc. The text details the terms of the merger agreement, conditions for completion, and related financing commitments. It also references a joint press release and an investor conference call presentation related to the merger. The document does not contain financial statements or detailed financial analysis but focuses on the announcement of the merger transaction and related agreements. This fits the definition of M&A Activity filings, which cover announcements and documents related to merger proposals or takeover bids. The document is lengthy (over 13,000 characters) and contains substantive information about the merger agreement, not just a brief announcement or a report publication notice. Therefore, the appropriate classification is M&A Activity (TAR).
2016-04-28 English
425 Filing
Call Transcript Classification · 100% confidence The document is a transcript of a conference call held by Abbott Laboratories regarding its agreement to acquire St. Jude Medical, Inc. The text includes detailed discussion of the merger and acquisition transaction, financial terms, strategic rationale, and Q&A with analysts. It references the filing of a Form S-4 registration statement and a proxy statement prospectus related to the transaction. The content is a full transcript of a call discussing an M&A deal, not a brief announcement or a regulatory filing. Therefore, the document fits the category of a Call Transcript (CT) related to M&A activity, but since it is a full transcript of the call, the best classification is Call Transcript (CT).
2016-04-28 English
425 Filing
M&A Activity Classification · 95% confidence The document is a fact sheet announcing Abbott Laboratories' agreement to acquire St. Jude Medical, Inc. It includes transaction details such as consideration per share, expected synergies, and financial highlights of both companies. It references the filing of a Form S-4 registration statement and a proxy statement/prospectus related to the transaction, which will be filed with the SEC. The document is not a full merger proxy statement or registration statement itself but rather an announcement and summary of the transaction terms and related procedural information. It is filed pursuant to Rule 425 under the Securities Act of 1933 and Rule 14a-12 of the Securities Exchange Act of 1934, which are rules for filing communications related to mergers and acquisitions. Given the content and regulatory references, this document fits best under the category of M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids.
2016-04-28 English
425 Filing
M&A Activity Classification · 95% confidence The document is filed pursuant to Rule 425 under the Securities Act of 1933 and Rule 14a-12 of the Securities Exchange Act of 1934, which are related to merger communications and proxy solicitation. The text discusses the acquisition of St. Jude Medical by Abbott Laboratories and mentions that a registration statement on Form S-4 will be filed, which includes a proxy statement/prospectus. It also urges investors to read the forthcoming proxy statement/prospectus and other documents when they become available. The document contains forward-looking statements and information about solicitation participants but does not contain actual financial data or detailed financial reports. The document is essentially a communication related to a merger transaction and proxy solicitation but is not the merger proxy statement itself or a full merger filing. Given the nature of the document as a Rule 425 filing (a type of merger communication), the most appropriate classification is Merger & Acquisition (MA).
2016-04-28 English
425 Filing
M&A Activity Classification · 95% confidence The document is a Form 8-K filed with the SEC by Abbott Laboratories dated April 27, 2016. It announces the entry into a material definitive agreement, specifically an Agreement and Plan of Merger with St. Jude Medical, Inc. The text details the terms of the merger agreement, conditions for completion, and related financing commitments. It also references a joint press release and an investor conference call presentation related to the merger. The document is primarily an announcement of a merger agreement and related financing arrangements, not a full merger proxy statement or detailed merger filing. It is not an annual or quarterly report, earnings release, or other financial report. The content fits the category of M&A Activity announcements, which include merger proposals and takeover bids. Therefore, the appropriate classification is M&A Activity (Code: TAR). The document length (over 13,000 characters) and detailed content support this classification with high confidence.
2016-04-28 English

Browse filings by year

33 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.